-+ 0.00%
-+ 0.00%
-+ 0.00%

Samsung EPIS Confirms Bioepis Brazil Supply Deal, Says Volumes and Pricing Remain Undecided

PUBT·10/21/2026 01:53:40
Listen to the news
Samsung EPIS Confirms Bioepis Brazil Supply Deal, Says Volumes and Pricing Remain Undecided
  • Samsung EPIS Holdings confirmed subsidiary Samsung Bioepis signed an exclusive SB12 supply agreement under Brazil’s government-led Productive Development Partnership.
  • SB12 is a biosimilar of Soliris, containing eculizumab, for rare diseases.
  • The clarification addresses October 21, 2026, media reports of a 10-year exclusive supply deal in Brazil.
  • Additional supply contracts are needed to implement the agreement; quantities and prices have not been determined.
  • A further disclosure is planned by November 20, 2026, or when additional contract terms trigger disclosure requirements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung EPIS Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021800142), on October 21, 2026, and is solely responsible for the information contained therein.